Oncotarget

Research Papers:

MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2

Qiang Xiao _, Yu Yang, Qing An and Yong Qi

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:34678-34686. https://doi.org/10.18632/oncotarget.16149

Metrics: PDF 1562 views  |   HTML 1630 views  |   ?  


Abstract

Qiang Xiao1, Yu Yang1, Qing An1 and Yong Qi1

1Department of Hand Surgery, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121001, China

Correspondence to:

Qiang Xiao, email: qiang_xiao14@163.com, xx6990@sina.com.cn

Keywords: osteosarcoma (OS), ZNRF2, miR-100, cancer growth, chemo-resistance

Received: January 23, 2017    Accepted: February 15, 2017    Published: March 13, 2017

ABSTRACT

Osteosarcoma (OS) is a prevalent cancer worldwide. MicroRNAs (miRNAs) play critical roles in the growth, invasion and carcinogenesis of OS, whereas the underlying mechanisms remain ill-defined. Here, we addressed these questions. We detected significantly higher levels of ZNRF2, a ubiquitin ligase of the RING superfamily, and significantly lower levels of miR-100 in the OS specimens, compared to the paired normal bone tissues. The levels of ZNRF2 and miR-100 inversely correlated in the OS specimens. In addition, low miR-100 levels are associated with poor prognosis of the OS patients. Either ZNRF2 overexpression or miR-100 depletion increased in vitro OS cell growth and improved cell survival at the presence of Doxorubicin. Mechanistically, with the help of bioinformatics analysis and luciferase-reporter assay, we found that miR-100 might bind to the 3’-UTR of ZNRF2 mRNA to prevent its protein translation. Thus, our data suggest that re-expression of miR-100 may inhibit OS cell growth and decrease OS cell chemo-resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16149